Global Heparin Market: Key Trends
The prevalence of coagulation disorders such as venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) has remarkably increased in both Europe and North America. Since heparin is one of the foremost clinical anticoagulants, the rising incidence of coagulation disorders will in turn fuel demand for heparin products, finds Transparency Market Research (TMR). Currently, heparin manufacturers are focusing on the development of generic versions of heparin to gain a competitive advantage in the market.
Naturally derived heparin products can cause severe side-effects in the event of an overdose. Scientists are therefore developing synthetic heparin products, which are both safer and cheaper. While declining imports from China will emerge as a major growth bottleneck, with the advent of biosimilars, heparin manufacturers will witness improved scope for expanding their product portfolio.
According to TMR, the global heparin market stood at US$8.2 bn in 2014. Exhibiting a CAGR of 6.3% between 2015 and 2023, the market is expected to reach US$14.3 bn by the end of 2023.
North America Reports Highest Demand for Heparin Due to Rising Prevalence of Coagulation Disorders
Regionally, North America emerged as the largest market for heparin products in 2014. As per the Centers of Disease Control and Prevention (CDC), nearly 900,000 people in the U.S. are affected by DVT and PE every year. Moreover, due to the sophisticated healthcare infrastructure the country boasts, the U.S. is visited by an increasing number of medical tourists annually. The overall number of surgical procedures conducted in the country is thus comparatively higher. This fuels demand for heparin products from North America. TMR projects the North America heparin market to rise at a CAGR of 6.3% between 2014 and 2023.
Europe emerged as the second largest market for heparin products in the same year. The U.K., Germany, and France are the most lucrative markets for heparin in the region. However, as per Transparency Market Research, the heparin market in Asia Pacific is expected to exhibit the fastest growth during the forecast period. The incidence of VTE has nearly doubled in India in the last decade.
Despite economic growth witnessed across the emerging nations of Asia Pacific, the unavailability of appropriate diagnostic centers and lack of awareness are leading to a lesser number of cases of DVT being reported. Nevertheless, GDP growth, increasing spending in healthcare infrastructure, and rising geriatric population are expected to fuel demand for heparin from Asia Pacific in the forthcoming years.
Low Molecular Weight Heparins Emerge as Standard Choice of Drug Care for Arterial and Venous Thrombosis
The most commonly used heparin products include ultra-low molecular weight heparin (ULMWH), low molecular weight heparin (LMWH), and unfractionated heparin. Although the demand for LMWHs is higher, the choice of heparin depends on the disease and patient’s condition. Low molecular weight heparins offer proven benefits over unfractionated heparins, due to which the demand for the former is rising at a higher pace.
Currently, LMWHs are considered the standard choice of care drugs for the treatment of arterial and venous thrombosis. This category of heparins also exhibits comparatively lesser side-effects, which is expected to bolster their sales in the forthcoming years. According to TMR, the LMWHs segment is expected to reach US$12.3 bn by the end of 2023. Demand from the ULMWHs segment is expected increase due to the rising use of these anticoagulants as an alternative to unfractionated heparin in dialysis.
Some of the leading players operating in the market are Fresenius Kabi AG, Dr. Reddy's Laboratories Ltd., Mylan N.V., LEO Pharma A/S, Pfizer, Inc., Syntex S.A., Sanofi S.A., and Teva Pharmaceutical Industries Ltd.
Heparin is an anticoagulant that is primarily used to prevent and treat venous thrombosis, pulmonary embolism, and other conditions of blood clotting. This report provides in-depth analysis of the global heparin market. Stakeholders for this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market. The global heparin market has been studied from two perspectives: by products and by geography. The heparin market, by products, comprises unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. A detailed market analysis and forecast for each of these segments have been provided in this study in terms of market revenue (USD million) for the period from 2013 to 2023. The report also provides compounded annual growth rate (CAGR %) for each of these segments for the forecast period from 2015 to 2023, considering 2013 and 2014 as historical and base years, respectively. Furthermore, the heparin market, by geography, includes North America, Europe, Asia Pacific, and Rest of the World. Each of these regions has been sub-segmented and analyzed for major contributing countries.
The market overview section of the report demonstrates major market dynamics such as drivers, restraints and opportunities that influence the current and future status of this industry. The market overview section includes Porter’s Five Forces Analysis and market attractiveness analysis by geography coupled with qualitative analysis on regulatory scenarios, impact analysis of key industry events, and value chain analysis to provide a thorough analysis of the overall competitive scenario in the global heparin market. The market overview section of the report also includes the qualitative and quantitative analysis of the competitive landscape.
Market share analysis is also provided in the market overview section of the report for 2014 in terms of value (%). The report also provides important recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market share and help new companies establish their presence in the heparin market in Europe. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Key players mentioned in the report include Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, LEO Pharma A/S, Mylan N.V., Pfizer, Inc., Sanofi S.A., Syntex S.A., and Teva Pharmaceutical Industries Ltd.
The global heparin market is segmented into the following categories:
Global Heparin Market, by Product
- Unfractionated Heparin
- Low Molecular Weight Heparin (LMWHs)
- Ultra-low Molecular Weight Heparin (ULMWHs)
Global Heparin Market, by Geography
- North America
- United States
- United Kingdom
- Rest of the Europe
- Asia Pacific
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Other Countries